α1 – Antitrypsin for Treatment of Acute Graft Versus Host Disease in Children and Young Adults

Key Points

• Treatment with α1-antitrypsin shows promise for improving outcomes in acute graft versus host disease.
• Key evidence includes improvement in treatment outcomes for 60% of children and young adults.
• Analysis of clinical data suggests that earlier intervention with α1-antitrypsin may reduce severity.
• Highlights the need for further studies in diverse populations for better generalizability.